{
  "id": "e7a89ce5c33205ba",
  "title": "Dr Vulsteke on the FDA Approval of Enfortumab Vedotin Plus Pembrolizumab for Cisplatin - Ineligible MIBC",
  "description": "20260108T020000Z",
  "content": "",
  "source": "onclive.com",
  "source_url": "https://www.onclive.com/view/dr-vulsteke-on-the-fda-approval-of-enfortumab-vedotin-plus-pembrolizumab-for-cisplatin-ineligible-mibc",
  "published_at": "20260108T020000Z",
  "fetched_at": "2026-01-09T00:23:18.491015+00:00",
  "category": "health_biotech",
  "subcategory": null,
  "keywords": [
    "fda"
  ],
  "location": "United States",
  "raw_data": {
    "url": "https://www.onclive.com/view/dr-vulsteke-on-the-fda-approval-of-enfortumab-vedotin-plus-pembrolizumab-for-cisplatin-ineligible-mibc",
    "url_mobile": "",
    "title": "Dr Vulsteke on the FDA Approval of Enfortumab Vedotin Plus Pembrolizumab for Cisplatin - Ineligible MIBC",
    "seendate": "20260108T020000Z",
    "socialimage": "https://cdn.sanity.io/images/0vv8moc6/onclive/f1d7b070f16477d2f8dee17162df6c0fd787df26-1280x720.png",
    "domain": "onclive.com",
    "language": "English",
    "sourcecountry": "United States"
  }
}